TOLREMO treats first patient in phase I trial with TT125-802, a novel therapeutic agent to overcome transcriptional cancer drug resistance

TOLREMO today announced that the first patient has been dosed in its first-in-human clinical trial evaluating the safety and tolerability, pharmacokinetics, and pharmacodynamics of its…
lenka30.11.2023